Matches in SemOpenAlex for { <https://semopenalex.org/work/W2884716004> ?p ?o ?g. }
- W2884716004 endingPage "3028" @default.
- W2884716004 startingPage "3028" @default.
- W2884716004 abstract "Abstract Background. New standards with increasing efficacy that are also characterized with improving the quality of life are needed for elderly myeloma patients. Although MPT and MPV regimens are remarkable in terms of efficacy, quality of life while on treatment with these 2 regimens remain an issue. The Carmysap twice weekly carfilzomib-based phase 2 study has demonstrated that Carfilzomib at the MTD of 36mg/m² might challenge bortezomib in the VMP standard. However, it has become routine practice to use bortezomib on a weekly schedule, with maintained efficacy and an improved safety profile. We sought to demonstrate that Carfilzomib Weekly plus Melphalan and Prednisone will prove strongly efficacious with acceptable safety profile and quality of life to newly diagnosed elderly multiple myeloma (eNDMM). Methods . IFM2012-03 (also called carmysap weekly) is a phase 1/2 multicenter open label single arm study to determine MTD during the phase 1 part and VGPR+CR rate during the phase 2 part of the study. The inclusion/exclusion criteria of interest were eNDMM (65 and older), with symptomatic and measurable disease, with absolute neutrophils ≥1 G/L, untransfused platelet count ≥75 G/L, hemoglobine ≥8.5 g/dL and clairance creatinine ≥ 30ml/min. We report herein the phase 1 part of the study which last cohort was completed at ASH abstract deadline. For the phase 1 part of the study, each cohort was 6 patients based, and started at 36mg/m² of carfilzomib on days 1, 8, 15, 22 using IV, 30 minutes infusion, route followed by a 13-day rest period per 35-days cycles, melphalan given at 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4. The subsequent cohorts' doses for carfilzomib were 45, then 56 and finally 70mg/m². 9 cycles were planned as induction followed by a maintenance phase of weekly carfilzomib monotherapy given at 36mg/m² weekly for one year. The MTD was determined when ˃2 DLTs were observed. DLTs were considered during cycle 1 if any hematologic toxicity of grade 4 intensity or preventing administration of 2 or more of the 4 carfilzomib doses of the first treatment cycle, grade ≥3 febrile neutropenia, grade ≥3 gastrointestinal toxicities, any other grade ≥3 nonhematologic toxicity considered related to CMP by the principal investigator, grade ≥ 3 peripheral neuropathy persisting for more than 3 weeks after discontinuation of study drugs. Results. 26 NDMM patients recruited, 24 treated in the study, 6 per cohort at 36 mg/m² carfilzomib +MP, then 45 then 56, and finally at 70mg/m² which cohort cycle 1 is up and running. The median age was 74 with 10 patients older than 75 and sex ratio M/F 65. There was a DLT at 36 mg/m² carfilzomib (grade 4 lymphopenia), one at 45 (lysis syndrome complicated with grade 4 renal insufficiency, two at 56 (cardiac insufficiency grade 3 and febrile neutropenia grade 3). At ASH deadline, all patients from cohort 36 of carfilzomib have completed induction and maintenance up to cycle 6, 5/6 of cohort 45 have completed induction and started the maintenance phase, 5/6 of cohort 56 have completed cycle 6 of induction and pursue within the induction phase, and finally all patients from cohort 70 of carfilzomib are undergoing cycle 1. There are 22 SAE reported for a total of 171 cycles administered of carfilzomib +MP. So far, 3 patients (out of 24) have stopped treatment, including the 2 patients with DLTs, lysis syndrome and cardiac failure, and one patient that presented with pulmonary hypertension later in the disease course on cycle 5 of the 56mg/m² carfilzomib +MP cohort. And, an extra 3 patients have had Carfilzomib dose reduction, 2 patients at 36 from 45 and one at 45 from 56, for neutropenia grade 4, thrombocytopenia grade 4, and Dyspnea grade 3, respectively. Conclusion. The MTD of weekly carfilzomib in the combination to Melphalan and Prednisone could be determined at 70mg/m² in elderly NDMM, demonstrating the good safety profile of carfilzomib in this regimen and fragile population. The complete dataset of the entire study will be updated at ASH with response rate, survival and safety profile. Disclosures Leleu: Chugai: Honoraria; LeoPharma: Honoraria; Pierre Fabre: Honoraria; BMS: Honoraria; Novartis: Honoraria; TEVA: Honoraria; Amgen: Honoraria; Takeda: Honoraria; Celgene: Honoraria; Janssen: Honoraria. Karlin:Janssen: Honoraria; BMS: Honoraria; Amgen: Honoraria; Sandoz: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria. Fitoussi:Sandoz: Membership on an entity's Board of Directors or advisory committees. Moreau:Bristol-Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen-Cilag: Honoraria, Membership on an entity's Board of Directors or advisory committees; Millennium: Honoraria, Membership on an entity's Board of Directors or advisory committees." @default.
- W2884716004 created "2018-08-03" @default.
- W2884716004 creator A5000760104 @default.
- W2884716004 creator A5000761302 @default.
- W2884716004 creator A5004897638 @default.
- W2884716004 creator A5014517118 @default.
- W2884716004 creator A5021314773 @default.
- W2884716004 creator A5025404578 @default.
- W2884716004 creator A5025996929 @default.
- W2884716004 creator A5026625329 @default.
- W2884716004 creator A5027311948 @default.
- W2884716004 creator A5029672826 @default.
- W2884716004 creator A5030255098 @default.
- W2884716004 creator A5033070003 @default.
- W2884716004 creator A5036292176 @default.
- W2884716004 creator A5038045164 @default.
- W2884716004 creator A5038965613 @default.
- W2884716004 creator A5042776012 @default.
- W2884716004 creator A5043695215 @default.
- W2884716004 creator A5044912720 @default.
- W2884716004 creator A5046391226 @default.
- W2884716004 creator A5048560248 @default.
- W2884716004 creator A5049929692 @default.
- W2884716004 creator A5051208529 @default.
- W2884716004 creator A5060956664 @default.
- W2884716004 creator A5061525651 @default.
- W2884716004 creator A5062417227 @default.
- W2884716004 creator A5067096291 @default.
- W2884716004 creator A5069449708 @default.
- W2884716004 creator A5071408501 @default.
- W2884716004 creator A5071589084 @default.
- W2884716004 creator A5072935581 @default.
- W2884716004 creator A5083431639 @default.
- W2884716004 creator A5083707252 @default.
- W2884716004 creator A5083854975 @default.
- W2884716004 creator A5086774598 @default.
- W2884716004 creator A5089853890 @default.
- W2884716004 date "2015-12-03" @default.
- W2884716004 modified "2023-10-01" @default.
- W2884716004 title "Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)" @default.
- W2884716004 doi "https://doi.org/10.1182/blood.v126.23.3028.3028" @default.
- W2884716004 hasPublicationYear "2015" @default.
- W2884716004 type Work @default.
- W2884716004 sameAs 2884716004 @default.
- W2884716004 citedByCount "1" @default.
- W2884716004 countsByYear W28847160042018 @default.
- W2884716004 crossrefType "journal-article" @default.
- W2884716004 hasAuthorship W2884716004A5000760104 @default.
- W2884716004 hasAuthorship W2884716004A5000761302 @default.
- W2884716004 hasAuthorship W2884716004A5004897638 @default.
- W2884716004 hasAuthorship W2884716004A5014517118 @default.
- W2884716004 hasAuthorship W2884716004A5021314773 @default.
- W2884716004 hasAuthorship W2884716004A5025404578 @default.
- W2884716004 hasAuthorship W2884716004A5025996929 @default.
- W2884716004 hasAuthorship W2884716004A5026625329 @default.
- W2884716004 hasAuthorship W2884716004A5027311948 @default.
- W2884716004 hasAuthorship W2884716004A5029672826 @default.
- W2884716004 hasAuthorship W2884716004A5030255098 @default.
- W2884716004 hasAuthorship W2884716004A5033070003 @default.
- W2884716004 hasAuthorship W2884716004A5036292176 @default.
- W2884716004 hasAuthorship W2884716004A5038045164 @default.
- W2884716004 hasAuthorship W2884716004A5038965613 @default.
- W2884716004 hasAuthorship W2884716004A5042776012 @default.
- W2884716004 hasAuthorship W2884716004A5043695215 @default.
- W2884716004 hasAuthorship W2884716004A5044912720 @default.
- W2884716004 hasAuthorship W2884716004A5046391226 @default.
- W2884716004 hasAuthorship W2884716004A5048560248 @default.
- W2884716004 hasAuthorship W2884716004A5049929692 @default.
- W2884716004 hasAuthorship W2884716004A5051208529 @default.
- W2884716004 hasAuthorship W2884716004A5060956664 @default.
- W2884716004 hasAuthorship W2884716004A5061525651 @default.
- W2884716004 hasAuthorship W2884716004A5062417227 @default.
- W2884716004 hasAuthorship W2884716004A5067096291 @default.
- W2884716004 hasAuthorship W2884716004A5069449708 @default.
- W2884716004 hasAuthorship W2884716004A5071408501 @default.
- W2884716004 hasAuthorship W2884716004A5071589084 @default.
- W2884716004 hasAuthorship W2884716004A5072935581 @default.
- W2884716004 hasAuthorship W2884716004A5083431639 @default.
- W2884716004 hasAuthorship W2884716004A5083707252 @default.
- W2884716004 hasAuthorship W2884716004A5083854975 @default.
- W2884716004 hasAuthorship W2884716004A5086774598 @default.
- W2884716004 hasAuthorship W2884716004A5089853890 @default.
- W2884716004 hasConcept C126322002 @default.
- W2884716004 hasConcept C141071460 @default.
- W2884716004 hasConcept C143998085 @default.
- W2884716004 hasConcept C2776063141 @default.
- W2884716004 hasConcept C2776364478 @default.
- W2884716004 hasConcept C2777478702 @default.
- W2884716004 hasConcept C2778684742 @default.
- W2884716004 hasConcept C2778720950 @default.
- W2884716004 hasConcept C2780108899 @default.
- W2884716004 hasConcept C71924100 @default.
- W2884716004 hasConcept C72563966 @default.
- W2884716004 hasConcept C98274493 @default.
- W2884716004 hasConceptScore W2884716004C126322002 @default.
- W2884716004 hasConceptScore W2884716004C141071460 @default.
- W2884716004 hasConceptScore W2884716004C143998085 @default.
- W2884716004 hasConceptScore W2884716004C2776063141 @default.